TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)
← catalyst calendarNCT06924099 · readout in 896 d
Sponsored by NovoCure Ltd. (industry) · NVCR — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
430estimated
Sites
24
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-11 | actual | When the study began enrolling |
| Primary completion | 2029-01-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glioblastoma
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured through study completion, an average of 18 months (mean FU time)
Permalink · NVCR's whole pipeline · Catalyst calendar · Every registered study · What changed